Glycopyrronium Axiromed (Glycopyrronium Bromide)

Glycopyrronium Axiromed is indicated for the long‑term management of airflow limitation in specific respiratory disorders.

• Chronic obstructive pulmonary disease (COPD) to reduce exacerbations.
• Stable bronchospasm associated with COPD.
• Maintenance therapy for patients who require anticholinergic bronchodilation.
• Adjunctive use when a single bronchodilator does not provide adequate symptom control.
• Part of combination therapy in patients needing additional bronchodilation.

The safety profile of Glycopyrronium Axiromed includes both frequently observed and less common adverse events.

Common

• Dry mouth.
• Cough.
• Throat irritation.
• Upper respiratory tract infection.
• Headache.

Serious

• Paradoxical bronchospasm.
• Severe allergic reaction (anaphylaxis).
• Cardiovascular events such as tachycardia.
• Urinary retention.
• Acute angle‑closure glaucoma.

Before prescribing Glycopyrronium Axiromed, clinicians should consider several precautionary factors.

• Use with caution in patients with narrow‑angle glaucoma.
• Avoid in individuals with known hypersensitivity to glycopyrronium or other anticholinergics.
• Assess cardiac history, as anticholinergic effects may increase heart rate.
• Monitor renal impairment, since the drug is excreted unchanged.
• Use carefully in pregnant or breastfeeding women; safety data are limited.
• Consider potential urinary retention in patients with prostate enlargement.
• Review concomitant use of other bronchodilators for additive effects.

Glycopyrronium Axiromed may interact with other medications, influencing efficacy or safety.

Avoid

• Concurrent use with other anticholinergic agents (e.g., ipratropium) may increase anticholinergic burden.
• Use of beta‑agonists in the same inhaler device if not recommended by the manufacturer.

Use with caution

• Beta‑adrenergic agonists (short‑acting or long‑acting) – monitor for additive bronchodilation.
• Antihistamines or tricyclic antidepressants – may enhance dry‑mouth effects.
• Drugs affecting heart rate (e.g., digoxin) – observe for tachycardia.
• Medications cleared renally – dose adjustment may be needed.
• Other inhaled corticosteroids – assess for combined respiratory effects.